Pediatric cancer community rattled by shortage of staple drug
A shortage of a cancer drug in the pediatric oncology community reportedly has doctors scrambling, as the sole producer left in the U.S. races to ramp up production. The drug, vincristine, was produced by both Teva Pharmaceuticals and Pfizer Inc. in the U.S. until July, when the former discontinued …